#United States #Kansas City #Clinical Trials #NextStage Clinical Research

NextStage Clinical Research Expands Its Clinical Trial Network in Kansas City

NextStage Clinical Research has proudly announced the opening of a new clinical research site in Kansas City, Missouri. This marks a significant expansion of their clinical trial network, aimed at enhancing research capabilities and patient access to innovative therapies. The facility is already operational and staffed with a dedicated team to ensure high-quality research and patient care.

As NextStage continues to broaden its influence in the clinical research field, the Kansas City site will play a crucial role in conducting Phases Ib through III clinical trials for various sectors, including biotechnology, pharmaceuticals, and medical devices. The site covers multiple specialties, particularly focusing on cardiovascular and orthopedic treatments.

Julie Rausch, Interim Chief Operating Officer of NextStage Clinical Research, expressed excitement about this new venture, underscoring the firm's commitment to accelerating medical innovation. "Our mission is to ensure patients have access to the latest therapies and treatment options. The Kansas City site represents another step in fulfilling this mission across the nation,” Rausch stated.

The strategic decision to establish a site in Kansas City is not just about expanding geographically; it aims to provide essential clinical research opportunities to the local population and the broader community. This initiative will contribute to advancing healthcare standards and herald new treatment alternatives for patients in the region.

NextStage’s focus is on collaboration with top-tier sponsors and healthcare professionals. By leveraging their expertise, the firm is determined to drive innovation in key therapeutic areas while maintaining high standards of patient safety, comfort, and outcomes. This commitment is evident from the company's track record since its founding, where it has consistently focused on study functionality and excellence.

Robert Schwing, Co-Founder and CEO of NextStage, elaborated on the long-term goals associated with this expansion. "The more locations and indications we can provide for biopharmaceutical clients, the more effectively we can help to advance medical knowledge and make a beneficial impact on public health. Our objective is to not only meet but also exceed our clients' needs, and opening new clinics is pivotal for achieving that goal!"

Overall, NextStage Clinical Research is dedicated to propelling medical science forward by executing high-quality clinical trials across a vast array of therapeutic areas. With research sites established in nine states throughout the continental U.S., the organization envisions steady growth while continuously enhancing clinical trial accessibility.

This new site in Kansas City signifies a meaningful advancement in the mission to improve healthcare and patient outcomes, allowing NextStage to empower its researchers and partners in the quest for innovative medical solutions, one clinical trial at a time.